Direct Evidences for Sympathetic Hyperactivity and Baroreflex Impairment in Tako Tsubo Cardiopathy

• Angelica Vaccaro ,

  Contributed equally to this work with: Angelica Vaccaro, Fabien Despas

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, C.I.C., Clinical Investigation Center, University Hospital of Toulouse, Toulouse, France

  ⨯
• Fabien Despas ,

  Contributed equally to this work with: Angelica Vaccaro, Fabien Despas

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, Toulouse University III Paul Sabatier, Toulouse, France, Clinical Pharmacology Department, University Hospital of Toulouse, Toulouse, France

  ⨯
• Clement Delmas,

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, Department of Cardiology, University Hospital of Toulouse, Toulouse, France

  ⨯
• Olivier Lairez,

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, Toulouse University III Paul Sabatier, Toulouse, France, Department of Cardiology, University Hospital of Toulouse, Toulouse, France

  ⨯
• Elisabeth Lambert,

  Affiliation Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Institute and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia

  ⨯
• Gavin Lambert,

  Affiliation Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Institute and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia

  ⨯
• Marc Labrunee,

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, Toulouse University III Paul Sabatier, Toulouse, France, Department of Cardiology, University Hospital of Toulouse, Toulouse, France

  ⨯
• Thibaut Guiraud,

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, Toulouse University III Paul Sabatier, Toulouse, France

  ⨯
• Murray Esler,

  Affiliation Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Institute and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia

  ⨯
• Michel Galinier,

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, Toulouse University III Paul Sabatier, Toulouse, France, Department of Cardiology, University Hospital of Toulouse, Toulouse, France

  ⨯
• Jean Michel Senard,

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, Toulouse University III Paul Sabatier, Toulouse, France, Clinical Pharmacology Department, University Hospital of Toulouse, Toulouse, France, Department of Cardiology, University Hospital of Toulouse, Toulouse, France

  ⨯
• Atul Pathak

  * E-mail: atul.pathak@univ-tlse3.fr

  Affiliations National Institute of Health and Medical Research (INSERM) UMR-1048, Institute of Metabolic and Cardiovascular diseases, Toulouse, France, Toulouse University III Paul Sabatier, Toulouse, France, Clinical Pharmacology Department, University Hospital of Toulouse, Toulouse, France, Department of Cardiology, University Hospital of Toulouse, Toulouse, France, Human Neurotransmitter Laboratory, Baker IDI Heart and Diabetes Institute and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia, C.I.C., Clinical Investigation Center, University Hospital of Toulouse, Toulouse, France

  ⨯